Natco Pharma on Wednesday announced that its marketing partner Alvogen has received the final approval of the Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg. Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart). Shares of Natco Pharma gained 1.12 per cent at ₹539.90 on the BSE.
Company news: Natco Pharma
Published on
May 8, 2019 23:30